Where scientific expertise meets cloud-based power:
Integrated collaboration, information storage, and sharing at your fingertips
Dr. David Schwartz of Innovative Science Solutions will be presenting at the upcoming 10th Annual Gibbons E-Discovery Conference being held in West Orange (New Jersey) on November 18, 2016.
This post was authored by Joseph Huggard, the General Manager of The Huggard Consulting Group who has spent more than 20 years working on a broad range of high profile issues with a particular emphasis on the use and communication of robust science, better regulation and regulatory impact assessment. Joe is highly regarded for his establishment of panels with high levels of scientific expertise and integrity which have produced influential findings on a variety of difficult issues.
The vast majority of malignant mesothelioma (MM) cases are asbestos related, yet the majority of individuals exposed to asbestos (even relatively high doses of amphibole asbestos fibers) do not develop MM. Many have concluded from this observation that there may be some genetic factor or factors that make some individuals more prone to mesothelioma than others -- perhaps even predestined to developing MM, even in the absence of asbestos exposure.
As we have highlighted in our blog over the past couple of years, there is a revolution underway in toxic tort litigation. This revolution involves the use of genomic data to define tumor types, to establish causation, and to establish alternate cause arguments. Genomic and other molecular science findings and legal issues continue to take on additional prominence across various subsets of "toxic tort" litigation, such as litigation involving benzene, dioxin, talc, silica and asbestos.
Consistent with our efforts to track scientific advances related to litigators, we are pleased to announce that we have recently updated our White Paper: New Science and Law in Asbestos Litigation (2016 Edition) (co-authored by our colleagues Kirk Hartley at the LSP Group and William Wilt at Assured Rearch).
On the science side, in this year's edition, we once again focus on the following topics:
Many lawyers involved with asbestos litigation recognize the importance of maintaining an awareness of the scientific literature related to genomics in the context of malignant mesothelioma (MM) and lung cancer (LC).
In a previous post, we outlined the positive impact of comprehensive science monitoring Science in The Courtroom: How to best prepare for a Science-Based Controversy.
In this post, we develop that theme and cover some remarkable use cases demonstrating how critical it is to maintain a robust mechanism to protect organizations from the ever-present threat of a science-based controversy. So, lets get into it.
Science plays a central role in many aspects of the corporate structure: legal cases, regulatory affairs, consumer and media outreach programs, and of course medical research and development. As a result it is critical for legal teams to maintain a keen awareness of the science related to their cases.